Design Therapeutics Inc (DSGN)
NASDAQ
News
Market Data
Register for streaming realtime charts, analysis tools, and prices.
Design Therapeutics Inc is a preclinical-stage biopharmaceutical company. It is a pioneering novel small-molecule therapeutic candidate, called gene-targeted chimera, that are designed to be disease-modifying and target the underlying cause of inherited nucleotide repeat expansion diseases. Design Therapeutics Inc is a preclinical-stage biopharmaceutical company. It is a pioneering novel small-molecule therapeutic candidate, called gene-targeted chimera, that are designed to be disease-modifying and target the underlying cause of inherited nucleotide repeat expansion diseases.
Ask ADVFN Intelligence (AI)
CARLSBAD, Calif., Sept. 10, 2024 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a biotechnology company developing treatments for serious degenerative genetic diseases, today...
Friedreich Ataxia (FA) and Fuchs Endothelial Corneal Dystrophy (FECD) Programs on Track and Advancing Toward Clinical Trials Active Research Pipeline with Programs Progressing in Myotonic...
| Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -0.345 | -6.13879003559 | 5.62 | 6.13 | 5.25 | 292890 | 5.75435047 | CS |
| 4 | -0.115 | -2.13358070501 | 5.39 | 6.91 | 4.5 | 424033 | 5.54300651 | CS |
| 12 | 2.025 | 62.3076923077 | 3.25 | 6.91 | 3.15 | 271202 | 5.02519316 | CS |
| 26 | 1.475 | 38.8157894737 | 3.8 | 6.91 | 3.15 | 267137 | 4.47091819 | CS |
| 52 | 2.925 | 124.468085106 | 2.35 | 6.91 | 1.96 | 300658 | 3.33504446 | CS |
| 156 | -9.745 | -64.880159787 | 15.02 | 26.3 | 1.94 | 347653 | 7.46007266 | CS |
| 260 | -22.725 | -81.1607142857 | 28 | 50 | 1.94 | 317915 | 8.54144203 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
